Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by AllinATE on Sep 26, 2022 3:52pm

Thinking out loud

Shouldn't trials be starting this week?
I wonder when the commercial study will be relased?
Also aren't they supposed to reveal IBD candidate in Q4?
Comment by MrMugsy on Sep 26, 2022 4:31pm
AllinATE - trials are supposed to start by 28th - not sure when they'd news release the first enrollment. Could release information on the study this week - OR - do they do a combo news release ?  IBD update ... by my estimate ... late in the year.  A 352 update could come before the IBD update ... or again ... could they package a 352/IBD update together ?  Hard to tell. So ...more  
Comment by TheMadMonk on Sep 26, 2022 5:52pm
AllinATE,   Please note that while the P2 molar trial is scheduled to start this week on the 28th, Dan did mention that it could be delayed a couple days.  The independent laboratory that tests and certifies the drugs to be used in the trial has been backed up and there is the chance that the start date of the trial may be delayed a few days.  If that happens don't ...more  
Comment by MrMugsy on Oct 01, 2022 8:39am
Timing for the commercial study update is likely tied to P2 start and first enrollment (study pushed out as well).  Since we didn't get either by Friday - highly likely we get it next week - assuming no serious delay.  Let's get this show on the road !
Comment by Inthepez on Oct 01, 2022 1:50pm
If not mistaken this molar study will be on healthy patients. Shouldn't see any issues SE wise in acute that's not a nocebo (opposite of placebo effect) 
Comment by MrMugsy on Oct 01, 2022 5:29pm
Agreed - we shouldn't see any odd side-effects but we do have something different this time around. I am assuming we will have a very high load dose - so - curious if that could have any strange effect on the body.  Hoping they have already figured that out. In terms of LTE's - we are time-limiting and self-correcting ... good controls to have in place when you're going after ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities